Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

FDA grants ZetrOZ US clearance to market sam wearable ultrasound therapy device

ZetrOZ has announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for the marketing of its ultrasound pain management device sam, a wearable, long-duration, ultrasonic diathermy device for use in applying deep therapeutic treatment.

In line with current clinical needs, sam, available by prescription, can be used to treat musculoskeletal and joint pain in adults. Clinical studies backing this technology demonstrate a measurable, drug-free decrease in pain via a wearable, non-invasive therapeutic patch.

sam is the first and only long duration continuous ultrasound therapy product that is FDA cleared for relief of pain, relief of muscle spasm, treatment of joint stiffness and increased local circulation.

"The device uses high-frequency ultrasonic excitations to produce deep mechanical stimulation within the body, increasing circulation, reducing inflammation and pushing nutrients through the body’s cellular structures," attests product inventor and company co-founder, George K. Lewis, Jr., Ph.D. who adds, "samĀ® is clinically proven to be an effective deep therapeutic treatment for select medical conditions and, when used daily provides added therapeutic benefit for chronic pain patients."

The rechargeable sam ultrasound therapy device can be worn daily for up to four hours on a single charge, providing continuous relief of pain or used as part of a rehabilitation program to increase local circulation of injured tissues for multiple hours.

sam can be prescribed and administered by a clinician or physical therapist, alone, or in tandem with other treatments. The leadership team behind sam, who were awarded a National Institutes of Health (NIH) grant of $397,000 to support clinical trials on knee osteoarthritis pain for the technology, plans to launch the device by spring of 2014.

sam is available by prescription from licensed healthcare practitioners such as primary care, orthopedists, rheumatologists, pain specialists and physiotherapists in the United States. In Europe and Canada, sam is CE-marked and licensed, respectively, and available over-the-counter directly to the patient.